CN113383959A - Preparation method of probiotic powder capable of eliminating antagonistic action among strains and obtained probiotic powder - Google Patents
Preparation method of probiotic powder capable of eliminating antagonistic action among strains and obtained probiotic powder Download PDFInfo
- Publication number
- CN113383959A CN113383959A CN202110512344.0A CN202110512344A CN113383959A CN 113383959 A CN113383959 A CN 113383959A CN 202110512344 A CN202110512344 A CN 202110512344A CN 113383959 A CN113383959 A CN 113383959A
- Authority
- CN
- China
- Prior art keywords
- probiotic powder
- eliminating
- steps
- strains
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 60
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 60
- 239000000843 powder Substances 0.000 title claims abstract description 58
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000003042 antagnostic effect Effects 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 230000008485 antagonism Effects 0.000 claims abstract description 17
- 238000007710 freezing Methods 0.000 claims abstract description 16
- 241001052560 Thallis Species 0.000 claims abstract description 15
- 238000000855 fermentation Methods 0.000 claims abstract description 15
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- 230000008014 freezing Effects 0.000 claims abstract description 15
- 239000002131 composite material Substances 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000013329 compounding Methods 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 244000005700 microbiome Species 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/427—Pentosaceus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Abstract
The invention discloses a preparation method of probiotic powder capable of eliminating the antagonistic action among strains and the obtained probiotic powder, belonging to the technical field of functional health food and medicines, and the preparation method comprises the following steps: s00, weighing required different strains in parts by weight; s10, independently culturing and fermenting strains to form a fermentation mixture; s20, separating thalli from the fermentation mixture through a centrifugal machine; s30, rapidly freezing the thalli within 3 seconds to reach the temperature of-196 ℃ to-210 ℃ from the room temperature, and drying the thalli into powder; and S40, adding the powder into a stirrer to be mixed to form the composite probiotic powder. The invention can solve the compounding problem that the components are not commonly used in probiotic powder products due to the antagonism problem.
Description
Technical Field
The invention relates to the technical field of functional health-care food and medicines, in particular to a preparation method of probiotic powder capable of eliminating the antagonistic action among strains and the obtained probiotic powder.
Background
The intestinal flora and normal microorganisms in the human intestinal tract, such as bifidobacteria, lactobacilli and the like, can synthesize various vitamins necessary for the growth and development of the human body, such as B vitamins (vitamin B1, B2, B6 and B12), vitamin K, nicotinic acid, pantothenic acid and the like, can also utilize protein residues to synthesize necessary amino acids, such as aspartic acid, phenylalanine, valine, threonine and the like, participate in the metabolism of saccharides and proteins, and can also promote the absorption of mineral elements such as iron, magnesium, zinc and the like. These nutrients have an important role in human health and cause various diseases if they are lacking. In addition to the functions of substance synthesis and metabolism, the relationship between the complex microbial ecosystem of the intestinal tract and the immune system of the body is also very close. The intestinal microorganisms not only can be used as a natural barrier to maintain the integrity of intestinal epithelium and prevent the invasion of pathogenic microorganisms, but also act on an intestinal immune system by regulating intestinal mucosa to secrete antibodies, and further influence natural immunity and acquired immunity, so the intestinal microorganisms are also considered as the largest 'immune organs' of a human body. The immune balance maintained by intestinal microorganisms plays an important role in the process of preventing autoimmune diseases of a body, when certain factors cause the change of intestinal flora, other immune systems of a human are further influenced, and the immune balance is easy to cause various diseases once being broken. More and more experimental evidence shows that intestinal microorganisms not only affect the functions of the human intestinal tract, but also affect the health of people from different angles and layers by regulating and controlling the immune system of the people.
In order to comprehensively improve the efficacy of products, various probiotic mixed preparations are sold in the market in a compounding mode, however, antagonism exists among some probiotics, so that the total effect of mixed probiotic substances is smaller than the sum of the separated effects of each substance, and the product is limited to the above, and at present, the commonly used compound probiotics in China only have more than 20 kinds, for example, lactobacillus plantarum and lactobacillus rhamnosus and lactobacillus casei have inhibition effects and are rarely added together, even if the compound probiotics are added, the efficacy is reduced or even disappears due to the antagonism process in the actual transportation process, and the problem becomes a big problem in the current food health science field, and the problem is urgently needed to be solved.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide a preparation method of probiotic powder capable of eliminating the antagonism among strains and the probiotic powder, and solve the problem of the antagonism among probiotics in the compounding process.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a preparation method of probiotic powder capable of eliminating antagonism among strains, which comprises the following steps:
s00: weighing different required strains according to the parts by weight;
s10: culturing and fermenting the strains independently to form a fermentation mixture;
s20: separating the thallus from the fermentation mixture by a centrifugal machine;
s30: the temperature of the thalli reaches from the room temperature of 196 ℃ below zero to 210 ℃ below zero within 3 seconds of quick freezing time, and the thalli are dried into powder;
the quick freezing time mentioned in the step S30 means the time required for the bacterial cells to be cooled from room temperature to a prescribed temperature;
s40: adding the powder into a stirrer to be mixed to form the composite probiotic powder.
In the preferred embodiment of the present invention, in step S30, the cells are flash-dried by liquid nitrogen.
The preferred technical scheme of the invention is that in the step S30, the quick freezing time is within 0.5-1.5 seconds.
The invention preferably adopts the technical scheme that in the step S30 and the step S30, the water activity of the powder is below 0.1.
The preferable technical scheme of the invention is that in the step S30, the survival rate of the thalli after being frozen suddenly is more than or equal to 95 percent.
The invention preferably adopts the technical proposal that in the step S20, the centrifugation is carried out for 10-15min at the rotating speed of 2500-.
The invention preferably adopts the technical scheme that in the step S40, the stirrer is used for stirring at a constant speed of 120-200 r/min.
The preferable technical scheme of the invention is that in the step S10, the fermentation temperature is 35-40 ℃, and the fermentation time is 6-12 h.
The invention preferably has the technical proposal that the amount of the probiotics in the fermentation mixture is 1-3 x 107cfu/mL。
The probiotic powder provided by the invention is prepared by the preparation method.
The preferable technical scheme of the invention is that the probiotic powder also comprises one or more of inulin, lactitol, isomaltooligosaccharide, polydextrose, fructo-oligosaccharide, resistant dextrin and xylo-oligosaccharide.
Compared with the prior art, the invention has the following beneficial effects:
(1) the thallus pre-freezing link abandons the traditional pre-freezing mode and adopts the quick-freezing technology. The frozen particles are formed instantly after the bacterial cells are frozen quickly, and water molecules inside and outside the cells can form small and smooth particles during crystallization, so that the damage of the bacterial cells caused by the puncture of cell membranes is avoided, and the integrity and the activity of the cells in the later freeze drying process are improved.
(2) Form frozen particles in the twinkling of an eye after freezing through the scrabble, can prevent the antagonistic action between the probiotic for the gross action after multiple probiotic material mixes can not receive reduction or decay, can make the probiotic powder of selling possess more comprehensive efficiency.
Drawings
FIG. 1 is a microscopic view of example 1, and FIG. 2 is a microscopic view of comparative example 1
Detailed Description
The present invention will be further described with reference to specific embodiments, but the present invention is not limited to the examples in any way. The starting reagents employed in the examples of the present invention are, unless otherwise specified, those that are conventionally purchased.
Examples 1 to 3 and comparative examples 1 to 2
A probiotic powder comprises the components shown in the following table 1 in parts by weight.
Table 1 ingredient contents (parts by weight) of the formulations
Examples 1 to 3
Examples 1-3 differ in the content of the components of the probiotic powder formulation.
Example 1 is directed to the inhibition antagonistic situation of Lactobacillus plantarum and Lactobacillus rhamnosus, Lactobacillus casei;
example 2 is directed to the inhibitory antagonistic effect profile of bifidobacterium lactis and lactobacillus rhamnosus, lactobacillus acidophilus;
example 3 is directed to the inhibitory antagonistic effect profile of Bifidobacterium bifidum and Lactobacillus plantarum, Lactobacillus rhamnosus.
The method comprises the following steps:
a preparation method of probiotic powder capable of eliminating the antagonism among strains comprises the following steps:
s00: weighing different required strains according to the parts by weight;
s10: the strain is cultured and fermented independently at 37 deg.C for 10 hr, and the probiotic bacteria content in the fermented mixture is 2.5 × 1011CFU/L, forming a fermentation mixture;
s20: separating thallus from the fermented mixture by a centrifugal machine, and centrifuging for 15min at the rotating speed of 2700 r/min;
s30: the thalli is frozen rapidly within 2 seconds under a vacuum environment to reach about-200 ℃, and is dried into powder, and the water activity of the powder is 0.08;
s40: adding the powder into a stirrer for mixing, and stirring at a constant speed of 180r/min by the stirrer to form the composite probiotic powder.
Comparative example 1
Comparative example 1 differs from example 1 in the freezing time of step S30, which is specifically as follows:
s00: weighing different required strains according to the parts by weight;
s10: the strain is cultured and fermented independently at 37 deg.C for 10 hr, and the probiotic bacteria content in the fermented mixture is 2.5 × 1011CFU/L, forming a fermentation mixture;
s20: separating thallus from the fermented mixture by a centrifugal machine, and centrifuging for 15min at the rotating speed of 2700 r/min;
s30: the thallus is rapidly frozen to about-200 ℃ within 6 seconds under a vacuum environment, and is dried into powder, and the water activity of the powder is 0.08;
s40: adding the powder into a stirrer for mixing, and stirring at a constant speed of 180r/min by the stirrer to form the composite probiotic powder.
Comparative example 2
The difference between comparative example 1 and example 1 is the water activity in step S30, which is specifically as follows:
s00: weighing different required strains according to the parts by weight;
s10: the strain is cultured and fermented independently at 37 deg.C for 10 hr, and the probiotic bacteria content in the fermented mixture is 2.5 × 1011CFU/L, forming a fermentation mixture;
s20: separating thallus from the fermented mixture by a centrifugal machine, and centrifuging for 15min at the rotating speed of 2700 r/min;
s30: the thallus is rapidly frozen to about-200 ℃ within 2 seconds under a vacuum environment, and is dried into powder, and the water activity of the powder is 0.18;
s40: adding the powder into a stirrer for mixing, and stirring at a constant speed of 180r/min by the stirrer to form the composite probiotic powder.
The test method comprises the following steps:
the prepared probiotic powder is placed at normal temperature for 12 months, and the activity and the total number of lactic acid bacteria are respectively tested.
Activity: testing by using a Proteases screening culture medium;
total number of lactic acid bacteria: testing according to GB 4789.35-2016;
the test results are shown in table 2.
Table 2 test data for one probiotic powder of the examples and comparative examples
Microscopic image of thallus:
after the complex probiotic powder prepared in example 1 and comparative example 1 was dissolved in water at 37 ℃, and observed under 400-fold microscope after 5 minutes, as shown in fig. 1 and 2.
According to the data of examples 1-3, it is shown that the activity of the probiotic powder prepared according to the invention is above 20000U and the concentration of lactic acid bacteria is 10 for different formulations with antagonistic action7Above cfu/mL, the interaction between probiotics which originally have antagonism can be well overcome, and the activity and the stability are maintained, so that the efficacy of the product is ensured.
Moreover, the formula components in the embodiment of the invention already cover all strains in a probiotic strain list which can be used for health-care food, can be applied and popularized as probiotic powder of all strains, and has important social value and economic value.
The rapid freezing speed is higher than that of the comparative example 1 in the embodiment 1, and the activity and the concentration of the lactobacillus bacteria are obviously improved, in the embodiment 1, the thalli cells are rapidly frozen into dry thalli, frozen particles are formed instantly after the thalli cells are rapidly frozen, water molecules inside and outside the cells can form small and smooth particles when being crystallized, the damage of the thalli caused by puncturing cell membranes is avoided, and the integrity and the activity of the cells in the later freeze drying process are improved. In contrast, in comparative example 1, water molecules inside and outside the bacterial cells may form uneven ice crystals due to slow freezing, so that the cells are punctured to cause cell death, and the normal morphology cannot be maintained, so that the activity and survival rate of example 1 in the data of table 2 are significantly higher than those of comparative example 1. Meanwhile, FIG. 1 shows a large amount of viable cells, while FIG. 2 shows only a small amount of viable cells. According to the invention, the stability of the probiotics after quick freezing is improved by the quick freezing method, the mutual action is reduced, and the anti-antagonistic effect is improved, so that the concentration of the lactobacillus in the example 1 in the data in the table 2 is obviously higher than that in the comparative example 1.
Water activity (aw) is an important factor that affects the stability of dried and dehydrated products during their manufacture and storage. The water activity of the dried or dehydrated product is controlled to maintain the correct texture, stability, density and rehydration. The higher the water activity, the poorer the stability of the probiotic and vice versa, the better. Example 1 is lower than comparative example 2 in water activity, and although both have little damaging effect on the rapid freezing process, the reduction in water activity further improves the stability of the probiotic, reduces the interaction between them, and improves the anti-antagonistic effect. Comparative example 2 the water activity was higher during the preparation process than in example 1, and the activity and stability of the probiotic product was reduced.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the spirit and scope of the invention. It is intended that the invention not be limited to the particular embodiment disclosed, but that the invention will include other embodiments falling within the scope of the appended claims.
Claims (10)
1. A preparation method of probiotic powder capable of eliminating antagonism among strains is characterized by comprising the following steps:
s00: weighing different required strains according to the parts by weight;
s10: the strains are independently cultured and fermented to form a fermentation mixture;
s20: separating thalli from the fermentation mixture by a centrifugal machine;
s30: the temperature of the thalli reaches from the room temperature of 196 ℃ below zero to 210 ℃ below zero within 3 seconds of quick freezing time, and the thalli are dried into powder;
s40: and adding the powder into a stirrer to be mixed to form the composite probiotic powder.
2. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in step S30, the cells are flash-freeze dried by liquid nitrogen method.
3. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in the step S30, the quick freezing time is within 0.5-1.5 seconds.
4. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in step S30, the water activity of the powder is below 0.1.
5. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in step S30, the survival rate of the thalli after being frozen quickly is more than or equal to 95 percent.
6. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in the step S20, centrifuging at 2500-.
7. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in the step S40, the stirrer stirs at a constant speed of 120-200 r/min.
8. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in the step S10, the fermentation temperature is 35-40 ℃, and the fermentation time is 6-12 h.
9. The method for preparing probiotic powder capable of eliminating the inter-species antagonism according to claim 1, wherein the method comprises the following steps:
in the step S10, the amount of probiotic bacteria in the fermentation mixture is 1-3 × 107cfu/mL。
10. A probiotic powder, characterized in that:
the probiotic powder is prepared by the preparation method of the probiotic powder capable of eliminating the antagonistic action among strains, which is disclosed by any one of claims 1 to 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110512344.0A CN113383959A (en) | 2021-05-11 | 2021-05-11 | Preparation method of probiotic powder capable of eliminating antagonistic action among strains and obtained probiotic powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110512344.0A CN113383959A (en) | 2021-05-11 | 2021-05-11 | Preparation method of probiotic powder capable of eliminating antagonistic action among strains and obtained probiotic powder |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113383959A true CN113383959A (en) | 2021-09-14 |
Family
ID=77616916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110512344.0A Pending CN113383959A (en) | 2021-05-11 | 2021-05-11 | Preparation method of probiotic powder capable of eliminating antagonistic action among strains and obtained probiotic powder |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113383959A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101503668A (en) * | 2009-03-06 | 2009-08-12 | 浙江大学 | Method for improving survival ratio of lactobacillus after freeze drying by liquid nitrogen prefreezing |
CN103333840A (en) * | 2013-07-08 | 2013-10-02 | 昆山佰生优生物科技有限公司 | Probiotic ultralow temperature refrigeration technology and applications thereof in probiotic preparation |
WO2019195791A1 (en) * | 2018-04-05 | 2019-10-10 | Xu Han | Improved ultra-fast cooling system and methods of use |
CN110408543A (en) * | 2019-07-17 | 2019-11-05 | 河北益存生物科技有限公司 | A kind of new probiotic bacterium ultralow temperature drying means |
CN112553128A (en) * | 2020-12-30 | 2021-03-26 | 瞿瀚鹏 | Probiotic freeze-dried powder and preparation method and application thereof |
-
2021
- 2021-05-11 CN CN202110512344.0A patent/CN113383959A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101503668A (en) * | 2009-03-06 | 2009-08-12 | 浙江大学 | Method for improving survival ratio of lactobacillus after freeze drying by liquid nitrogen prefreezing |
CN103333840A (en) * | 2013-07-08 | 2013-10-02 | 昆山佰生优生物科技有限公司 | Probiotic ultralow temperature refrigeration technology and applications thereof in probiotic preparation |
WO2019195791A1 (en) * | 2018-04-05 | 2019-10-10 | Xu Han | Improved ultra-fast cooling system and methods of use |
CN110408543A (en) * | 2019-07-17 | 2019-11-05 | 河北益存生物科技有限公司 | A kind of new probiotic bacterium ultralow temperature drying means |
CN112553128A (en) * | 2020-12-30 | 2021-03-26 | 瞿瀚鹏 | Probiotic freeze-dried powder and preparation method and application thereof |
Non-Patent Citations (3)
Title |
---|
FRE´DE´RIC DUMONT等: "Cell Size and Water Permeability as Determining Factors for Cell Viability after Freezing at Different Cooling Rates", 《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》 * |
王华等: "微生物液氮超低温保存研究进展", 《食品与生物技术学报》 * |
车云波: "《功能食品加工技术》", 31 January 2013, 北京:中国质检出版社,中国标准出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Massounga Bora et al. | Improved viability of microencapsulated probiotics in a freeze-dried banana powder during storage and under simulated gastrointestinal tract | |
Forssten et al. | Probiotics from an industrial perspective | |
EP1971209B1 (en) | Fermented milk or yoghurt powder with a high density of lactic ferments | |
CN111567669A (en) | Based on W1/O/W2Probiotic preparation with double-emulsion structure, preparation method and application | |
EP2547214B1 (en) | Dried fermented dairy product containing a high density of living bifidobacteria | |
KR101927859B1 (en) | Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component | |
CN111011867B (en) | Probiotic embedded particle and preparation method thereof | |
US9554583B2 (en) | Process for the production of freeze dried micro-organisms and related compositions | |
CN102972522A (en) | Probiotic milk and preparation method thereof | |
US20110287143A1 (en) | Temperature-induced delivery of nutrients by micro-organisms in the gastrointestinal tract | |
Abd-Elhamid | Production of functional kariesh cheese by microencapsulation of Bifidobacterium adolescentis ATCC 15704 | |
EP3328208B1 (en) | Methods for the preparation of fermented products comprising bifidobacteria | |
US20190053527A1 (en) | Method for preparing a probiotic powder using a two-in-one whey-containing nutrient medium | |
CN113383959A (en) | Preparation method of probiotic powder capable of eliminating antagonistic action among strains and obtained probiotic powder | |
CN1847391A (en) | Composite protectant for freeze dried fermenting prepn of directly thrown bifidobacterium | |
Grattepanche et al. | Production of viable probiotic cells | |
CN102106385B (en) | Milk beverage containing fruit wine and preparation method thereof | |
JP2012105577A (en) | Production method of whey fermented beverage | |
RU2425576C1 (en) | Dry probiotically active biopreparation and method for production of fermented milk drink based on it | |
KR102246957B1 (en) | Functional additives for enhancing immunity using lactic acid bacteria having beneficial effect on intestinal flora and methods for producing the same | |
US11638726B2 (en) | Methods for producing probiotics fortified avian eggs and egg products and formulations thereof | |
Hati et al. | Encapsulation of probiotics for enhancing the survival in gastrointestinal tract | |
CN115038341A (en) | Coated probiotics, food compositions comprising the coated probiotics and methods for producing the coated probiotics | |
AU2018285184B2 (en) | Microbial cell-containing non-carbonated liquid food/drink, and method for improving dispersibility of precipitates or agglomerates of microbial cell powder in food/drink | |
Kalantarmahdavi et al. | Viability of Lactobacillus plantarum incorporated with sourdough powder-based edible film in set yogurt and subsequent changes during post fermentation storage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zimeng Inventor after: Ding Xueru Inventor before: Zhang Zimeng |